IMWG Guidelines for the Use of Bisphosphonates in Myeloma

Posted · Add Comment

Intravenous bisphosphonate therapy has been amply demonstrated to reduce bone complications of myeloma.   Bisphosphonate (BP) therapy is therefore an important component of supportive care for myeloma patients with boney disease. Adverse events associated with BP are usually mild and consist of fever, renal function impairment, myalgias, and hypocalcemia.  A more serious potential side effect of bisphosphonate therapy that was first identified in 20031 is osteonecrosis of the jaw (ONJ), a debilitating problem that can be associated with significant morbidity. The following guidelines for the use of bisphosphonate therapy in myeloma are based upon IMWG and Mayo Clinic guidelines2,3 and are intended to provide safe criteria for bisphosphonate use to minimize […]

Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement.

Posted · Add Comment

The International Myeloma Working Group (IMWG), which comprises 85 investigators  specializing in the area of multiple myeloma, has reviewed and considered the recent Mayo Clinic consensus statement for the use of bisphosphonates (BPs) in multiple myeloma. Although the IMWG is in general agreement with the Mayo consensus statement, several important issues have been raised and are discussed subsequently. These comments are in response to the recommendations of  the Mayo group, which is normally part of the IMWG. Author: Durie BG Mayo Clin Proc. 2007 Apr;82(4):516-7; author reply 517-8. Click here to view Article